{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-285671","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.570713+00:00","generated_at":"2026-06-07T19:57:21.858715+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Benitec dosed first subject in Phase 1b/2a trial of BB-301 for OPMD dysphagia","bullets":["BB-301 is a gene therapy candidate using Silence and Replace ddRNAi platform for Oculopharyngeal Muscular Dystrophy (OPMD).","OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently exist.","Interim safety and efficacy data from the 52-week study expected in mid-2024.","19 subjects in the ongoing OPMD Natural History study are eligible to roll over into the BB-301 treatment study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-285671","json":"https://secwatch.observer/filing/0001193125-23-285671.json","markdown":"https://secwatch.observer/filing/0001193125-23-285671.md","text":"https://secwatch.observer/filing/0001193125-23-285671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/0001193125-23-285671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/d401028d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:57:21.858715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}